BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy

Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy.

“GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional responders to COVID-19. There’s never been anything like that before,” GigaGen CEO and co-founder David Johnson, Ph.D., told BioSpace. “We’re establishing a completely new type of drug.”

Read the full story.